GLP-1 receptor agonists (GLP-1RAs) with demonstrated cardiovascular benefits may also be suitable for patients with type 2 diabetes (T2D) who do not have established cardiovascular disease (CVD) but exhibit high-risk indicators. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.